<DOC>
	<DOCNO>NCT02183376</DOCNO>
	<brief_summary>To investigate influence mild , moderate , severe liver impairment pharmacokinetics pharmacodynamics linagliptin comparison control group normal hepatic function single multiple oral administration 5 mg linagliptin tablet</brief_summary>
	<brief_title>Pharmacokinetics Pharmacodynamics BI 1356 Subjects With Different Degrees Liver Impairment Compared Healthy Subjects</brief_title>
	<detailed_description />
	<mesh_term>Hepatic Insufficiency</mesh_term>
	<mesh_term>Linagliptin</mesh_term>
	<criteria>Patients hepatic impairment determine result screen classified mild ( ChildPugh class A , score 6 point ) , moderate ( ChildPugh class B , score 7 9 point ) severe ( ChildPugh class C , score 10 15 point ) Healthy male female base complete medical history , include physical examination , vital sign ( BP , PR ) , 12lead ECG , clinical laboratory test Subjects respective group match regard age ( ±10 year ) , weight ( ±20 % ) gender Age 18 70 year , inclusive Body mass index 18.5 29.9 kg/m2 , inclusive Creatinine clearance ≥80 mL/min ( except patient severe hepatic impairment , see exclusion criterion ) accord Cockroft &amp; Gault Signed date write informed consent prior admission study accordance good clinical practice local legislation Exclusion criterion subject Surgery gastrointestinal tract ( except appendectomy oesophageal varix ) Diseases central nervous system ( epilepsy ) psychiatric disorder neurological disorder ( except hepatoportal encephalopathy ) History relevant orthostatic hypotension , faint spell , blackout Chronic relevant acute infection ( except nonprogressive chronic hepatitis progressive state ) History relevant allergy hypersensitivity ( include allergy study drug excipients ) Use drug might reasonably influence result trial prolong QT QTc interval ( base knowledge time prepare Clinical Trial Protocol ) within 10 day prior study drug administration trial Participation another trial investigational drug within 2 month prior study drug administration trial Smoking ( 10 cigarette , 3 cigar , 3 pipe per day ) Inability refrain smoke trial day Alcohol abuse ( 60 g/day ) Drug abuse Blood donation ( &gt; 100 mL within 4 week prior study drug administration trial ) Excessive physical activity ( within 1 week prior study drug administration trial ) Inability comply dietary regimen trial site A marked baseline prolongation QT QTc interval ( e.g . repeat demonstration QTc interval &gt; 450 m ) A history additional risk factor torsade de pointes heart failure , severe hypokalemia ( &lt; 3.0 mmol/L ) , family history long QT syndrome Additional/modified exclusion criterion healthy volunteer Any find medical examination ( include BP , PR , ECG ) deviate normal clinical relevance Any evidence clinically relevant concomitant disease Intake drug long halflife ( &gt; 24 h ) within 1 month less 10 halflives respective drug prior study drug administration trial Any laboratory value outside reference range clinical relevance Additional/modified exclusion criterion patient hepatic impairment Decompensated gastrointestinal , respiratory , cardiovascular , metabolic , immunological , hormonal disorder Patients severe liver impairment ( ChildPugh C ) : Severe concurrent renal dysfunction ( e.g . due hepatorenal syndrome ) creatinine clearance &lt; 40mL/min Intake drug long halflife ( &gt; 24 h ) within 1 month less 10 halflives respective drug prior study drug administration trial intake metformin ; drug take treatment underlie disease exclude Any laboratory value outside reference range clinical relevance , except parameter relate liver impairment ( e.g . albumin , bilirubin , enzymes ) liver function test accord ChildPugh classification Additional exclusion criterion female subject Pregnancy intention become pregnant within 2 month study completion Positive pregnancy test Lack adequate contraception ( e.g . sterilisation , intrauterine device ) use barrier method contraception least 3 month prior study Unwillingness inability use reliable method barrier contraception ( e.g . diaphragm spermicidal cream jelly condoms spermicidal foam ) , study 2 month completion termination trial Unwillingness partner use condoms Lactation period</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>July 2014</verification_date>
</DOC>